Melinta Therapeutics, Inc. announced the FDA has approved Baxdela (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia...
Melinta Therapeutics, Inc has announced the FDA has accepted a supplemental New Drug Application (sNDA) for Baxdela (delafloxacin) for priority...
Melinta Therapeutics, a privately held company focused on discovering, developing, and commercializing novel antibiotics to treat serious bacterial infections, announced...
Melinta Therapeutics, announced top-line results from the second Phase III study (RX-3341-303, NCT01984684) of Baxdela (delafloxacin), an investigational anionic quinolone...
Ligand Pharmaceuticals Incorporated partner Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced that...
Melinta Therapeutics announced that The Menarini Group, Melinta�s commercial and co-development partner, has submitted a Marketing Authorization Application (MAA) to...